Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit/Hyperactivity Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

NCT02144415
View directory record Official record
Conditions
Healthy Volunteers, Drug Users
Interventions
EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

NCT03676725
View directory record Official record
Conditions
ADHD, PMS
Interventions
Lidocaine gel
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Dasotraline Pediatric Extension Study

NCT02457819
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Dothan, Alabama • Culver City, California • Wildomar, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

NCT00500071
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vyvanse (lisdexamfetamine dimesylate)
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
46
States / cities
Scottsdale, Arizona • El Centro, California • Rolling Hills Estates, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 5 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Text Messaging Adherence to Stimulant Medication

NCT01967485
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Text- Messaging, Treatment as usual
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Effect of Omega-3 Fatty Acid on Cortical Function in ADHD

NCT01883817
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder

NCT01275378
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Collaborative Care Plus, Traditional Collaborative Care
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 23, 2026, 3:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectroscopy in Children and Adolescents With Bipolar Disorder

NCT00181831
View directory record Official record
Conditions
Bipolar Disorder, ADHD
Interventions
Proton Magnetic Resonance Spectroscopy
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Testing "SupporT for ADHD and Related Treatment" (START) for Families of Children With ADHD

NCT05796427
View directory record Official record
Conditions
ADHD
Interventions
SupporT for ADHD and Related Treatment
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 4 Interventional

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

NCT00506727
View directory record Official record
Conditions
ADHD
Interventions
Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01

NCT03844269
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AKL-T01
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Rafael, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daytrana
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 3:57 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 23, 2026, 3:57 AM EDT
Withdrawn Not applicable Interventional

Mobile Health Solutions for Behavioral Skill Implementation Through Homework

NCT02662140
View directory record Official record
Conditions
Oppositional Defiant, Conduct Disorder
Interventions
Mobile Health Applictaion
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
View directory record Official record
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

NCT01107496
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
IR Viloxazine, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Four-week Open-trial Extension TNS for ADHD

NCT03870737
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Active TNS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 3:57 AM EDT
Terminated Not applicable Interventional Results available

Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors

NCT01749800
View directory record Official record
Conditions
TBI, Attention Deficits, Motor Impairments
Interventions
GVS, Sham GVS, Armeo Spring
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

NCT03247556
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 400mg SPN-812, 600mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 23, 2026, 3:57 AM EDT
Completed No phase listed Observational

Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

NCT02473419
View directory record Official record
Conditions
ADHD
Interventions
Vayarin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 23, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT02734693
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline 4mg, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 23, 2026, 3:57 AM EDT